Aurobindo Pharma gets final USFDA approval

Aurobindo Pharma on Thursday announced that it had received final approval from the United States Food and Drug Administration for its product Ceftazideme injection in different dosages. A company press release said Ceftazideme was indicated for treatment of infections caused by susceptible gram-negative bacilli such as septicemis, lower respiratory tract infections, abdominal cavity, biliary tract and complex urinary tract infections. With this approval, Aurobindo Pharma claimed it had 89 final approvals and 30 tentative approvals for its drugs.